- Home
- GH vs BCO Comparison
GH vs BCO Comparison
Compare GH & BCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- BCO
- Stock Information
- Founded
- GH 2011
- BCO 1859
- Country
- GH United States
- BCO United States
- Employees
- GH N/A
- BCO N/A
- Industry
- GH Medical Specialities
- BCO Oil Refining/Marketing
- Sector
- GH Health Care
- BCO Consumer Discretionary
- Exchange
- GH Nasdaq
- BCO Nasdaq
- Market Cap
- GH 4.9B
- BCO 4.2B
- IPO Year
- GH 2018
- BCO N/A
- Fundamental
- Price
- GH $54.62
- BCO $115.23
- Analyst Decision
- GH Strong Buy
- BCO Strong Buy
- Analyst Count
- GH 17
- BCO 1
- Target Price
- GH $58.24
- BCO $138.00
- AVG Volume (30 Days)
- GH 2.4M
- BCO 294.5K
- Earning Date
- GH 11-05-2025
- BCO 11-05-2025
- Dividend Yield
- GH N/A
- BCO 0.88%
- EPS Growth
- GH N/A
- BCO 24.94
- EPS
- GH N/A
- BCO 3.72
- Revenue
- GH $828,849,000.00
- BCO $5,069,900,000.00
- Revenue This Year
- GH $28.07
- BCO $5.33
- Revenue Next Year
- GH $21.61
- BCO $4.60
- P/E Ratio
- GH N/A
- BCO $31.37
- Revenue Growth
- GH 28.74
- BCO 2.17
- 52 Week Low
- GH $20.14
- BCO $80.10
- 52 Week High
- GH $68.00
- BCO $117.65
- Technical
- Relative Strength Index (RSI)
- GH 41.10
- BCO 65.81
- Support Level
- GH $53.67
- BCO $113.91
- Resistance Level
- GH $61.95
- BCO $117.65
- Average True Range (ATR)
- GH 2.29
- BCO 2.13
- MACD
- GH -1.51
- BCO -0.41
- Stochastic Oscillator
- GH 7.33
- BCO 66.98
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About BCO Brinks Company (The)
The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provides BGS services and BGS activity in Latin American countries. It derives maximum revenue from North America segment.